Can a common statin help kids with kidney disease and high cholesterol?

NCT ID NCT07497776

Completed Disease control Sponsor: National Institute of Kidney Disease and Urology (NIKDU) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 4 trial tested the drug atorvastatin (Lipitor) in 100 children aged 8-18 with steroid-sensitive nephrotic syndrome and high cholesterol. The goal was to see if the drug safely lowers cholesterol to healthy levels within 3 to 6 months. The study compared atorvastatin to a placebo or standard care to measure effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atorvastatin (a statin drug, also known as Lipitor)
What this could lead to: If it works, this could provide a safe way to manage high cholesterol in children with nephrotic syndrome, reducing heart risks.
What could go wrong: This is a small, completed Phase 4 trial with only 100 children. Results may not apply to all patients, and statins can have side effects like muscle pain or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder nephrotic syndrome nephrotic syndrome of childhood - steroid sensitive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDAEMIA

Contacts and locations

Locations

National Institute of kidney diseases and Urology

Dhaka, Dhaka Division, 1207, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.